GLUT1 regulates the release of VEGF‐A in the alveolar epithelium of lipopolysaccharide‐induced acute lung injury

Abstract Acute lung injury (ALI) is a severe disease with high mortality and poor prognosis, characterized by excessive and uncontrolled inflammatory response. Vascular endothelial growth factor A (VEGF‐A) contributes to the development and progression of ALI. The aim of this study was to evaluate the role of glucose transporter 1 (GLUT1) in alveolar epithelial VEGF‐A production in lipopolysaccharide (LPS)‐induced ALI. An ALI mouse model was induced by LPS oropharyngeal instillation. Mice were challenged with LPS and then treated with WZB117, a specific antagonist of GLUT1. For the vitro experiments, cultured A549 cells (airway epithelial cell line) were exposed to LPS, with or without the GLUT1 inhibitors WZB117 or BAY876. LPS significantly upregulated of GLUT1 and VEGF‐A both in the lung from ALI mice and in cultured A549. In vivo, treatment with WZB117 not only markedly decreased LPS‐induced pulmonary edema, injury, neutrophilia, as well as levels of interleukin (IL)‐1β, IL‐6 and tumor necrosis factor‐α in bronchoalveolar lavage fluid (BALF), but also reduced VEGF‐A production. Yet, the maximum tolerated concentration of WZB117 failed to suppress LPS‐induced VEGF‐A overexpression in vitro. While administration of BAY876 inhibited gene and protein expression as well as secretion of VEGF‐A in response to LPS in A549. These results illustrated that GLUT1 upregulates VEGF‐A production in alveolar epithelia from LPS‐induced ALI, and inhibition of GLUT1 alleviates ALI.